计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
O412011-1mg |
1mg |
现货 ![]() |
| |
O412011-5mg |
5mg |
现货 ![]() |
|
别名 | Gazyva; GA101; Gazyvaro; Afutuzumab; 奥滨尤妥珠单抗; 阿托珠单抗; APY antibody; ATOPY antibody; B lymphocyte antigen CD20 antibody; B Lymphocyte Cell Surface Antigen B1 antibody; B-lymphocyte antigen CD20 antibody; B-lymphocyte cell-surface antigen B1 antibody; B-lymp |
---|---|
英文别名 | Gazyva; GA101; Gazyvaro; Afutuzumab; APY antibody; ATOPY antibody; B lymphocyte antigen CD20 antibody; B Lymphocyte Cell Surface Antigen B1 antibody; B-lymphocyte antigen CD20 antibody; B-lymphocyte cell-surface antigen B1 antibody; B-lymphocyte surface a |
规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
英文名称 | Obinutuzumab (anti-CD20) |
稳定性与储存 | Store at -80℃ for 2 years. Avoid repeated freeze/thaw cycles. |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
来源 | CHO supernatant |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
产品介绍 |
Obinutuzumab是新型糖工程化 II 型 CD20 人源化 IgG1 单克隆抗体,用于非霍奇金淋巴瘤的研究。 Obinutuzumab is a novel glyca-engineered type II CD20 humanized IgG1 monoclonal antibody for non-Hodgkin lymphoma. |
IMGT/mAb-DB | 238 |
---|---|
Wikipedia | Obinutuzumab |
PubChem SID | 178103523 |
PEP | obinutuzumab |
输入批号以搜索COA:
Obinutuzumab (anti-CD20) (O412011) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Obinutuzumab (anti-CD20) (O412011). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Obinutuzumab (anti-CD20) (O412011) - SEC
The purity of Obinutuzumab (anti-CD20) (O412011) is more than 95% verified by HPLC.
1. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.. Mol Cancer Ther, 12 (10): (2031-42). [PMID:23873847] |